CEREVEL THERAPEUTICS HOLDINGS, INC.
222 Jacobs Street, Suite 200
Cambridge MA 02141
VIA EDGAR
November 16, 2022
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: Cerevel Therapeutics Holdings, Inc.
Acceleration Request for Registration Statement on Form S-3
Filed November 8, 2022
File No. 333-268235
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cerevel Therapeutics Holdings, Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to November 18, 2022, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable.
If you have any questions regarding this request, please contact Nicole Daley of Goodwin Procter LLP at (617) 570-1354.
| Sincerely, |
| CEREVEL THERAPEUTICS HOLDINGS, INC. |
| /s/ Mark Bodenrader |
| Mark Bodenrader |
| Interim Chief Financial Officer |
cc: N. Anthony Coles, Cerevel Therapeutics Holdings, Inc.
Scott M. Akamine, Cerevel Therapeutics Holdings, Inc.
John Mei, Cerevel Therapeutics Holdings, Inc.
Stuart M. Cable, Goodwin Procter LLP
Nicole Daley, Goodwin Procter LLP